Is hepatic glucose production increased in type 2 diabetes mellitus?

被引:0
作者
Beck-Nielsen H. [1 ]
Hother-Nielsen O. [1 ]
Staehr P. [1 ]
机构
[1] Department of Endocrinology M, Odense University Hospital, Kløvervaenget 6.4
关键词
Glucose Uptake; Glucose Production; Hepatic Glucose Production; Endogenous Glucose Production; Metabolic Clearance Rate;
D O I
10.1007/s11892-002-0088-0
中图分类号
学科分类号
摘要
Based on recent studies, including our own, using what we consider to be an appropriate technique to estimate rates of hepatic glucose production (HGP), this article can be summarized as follows: 1) HGP in the overnight fasted state is near normal in obese type 2 diabetes (T2D) subjects, i.e., it may be increased by a mean of 12% compared to matched control subjects. 2) Suppression of HGP by insulin shows a rightward shift of the dose response curve (reduced insulin sensitivity) but normal maximal suppression (no maximum velocity defect). 3) In the overnight fasted state, gluconeogenesis is responsible for two thirds of HGP in T2D subjects and is about 5% to 10% increased compared to healthy subjects. 4) Suppression of HGP during a meal is close to normal. 5) The slightly increased HGP values throughout the 24-hour period together with reduced metabolic clearance rate (peripheral insulin resistance) and increased carbohydrate intake is responsible for the increase in fasting plasma glucose values. 6) Hypothetically, the role of the liver in nondiabetic and T2D subjects may be to produce the amount of glucose needed for metabolism in peripheral tissues. If insulin-mediated glucose uptake in skeletal muscle is reduced, plasma glucose will increase due to the "nonsuppressed" HGP values. Plasma glucose continues to rise until glucose-mediated glucose uptake compensates completely for the reduction in insulin-mediated glucose uptake.
引用
收藏
页码:231 / 236
页数:5
相关论文
共 64 条
[1]  
Harris MI(1993)Undiagnosed NIDDM: clinical and public health issues Diabetes Care 16 642-652
[2]  
Pyorala K(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853
[3]  
Pedersen TR(1998)Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) BMJ 317 703-713
[4]  
Kjekshus J(1997)Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus Diabetes Care 20 614-620
[5]  
Beck-Nielsen H(1994)Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM J Clin Invest 94 1714-1721
[6]  
Groop LC(1988)Is muscle the major site of insulin resistance in type 2 (non-insulin-dependent) diabetes mellitus? Diabetes 37 667-687
[7]  
DeFronzo RA(1991)Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study Diabetologia 34 607-610
[8]  
Gerich JE(2000)Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: the role of skeletal muscle glucose uptake and hepatic glucose production in the development of hyperglycaemia. A critical comment Diabetes 49 1367-1373
[9]  
Gastaldelli A(1994)The fourth musketeer-from Alexandre Dumas to Claude Bernard Diabetologia 37 217-221
[10]  
Baldi S(1995)Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 hours of fasting Diabetologia 38 3-13